Navigation Links
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Date:4/23/2009

th pegylated interferon and ribavirin. The actual timing for the initiation of Phase II studies may depend on a number of factors, including FDA review timelines, the timing of any potential transaction around ANA598 or ANA773, available cash resources and funding activities, and the engagement of clinical sites.

14 Day Healthy Volunteer Study

Anadys recently completed dosing healthy volunteers in a 14-day study conducted to extend the safety and pharmacokinetic profile of ANA598. Thirty subjects participated in the study, with eight subjects receiving ANA598 and two subjects receiving placebo at each dose level (400 mg once-daily, 800 mg once-daily and 600 mg bid). Subjects received ANA598 or placebo on day one followed by pharmacokinetic assessment over days two and three and received subsequent doses consecutively on days four through fourteen. Preliminary results from the study indicate that ANA598 was generally well-tolerated in all cohorts with no serious adverse events, although three subjects receiving ANA598 (two in the 800 mg once-daily cohort and one in the 600 mg bid cohort) developed grade 2 rash and discontinued treatment after either six or seven days of consecutive dosing. There were no other instances of rash in this or any other study of ANA598. Data receipt and analysis from this study is continuing, and the Company expects to present the results at a clinical conference later this year. The Company believes the results of this study, combined with the results of the Phase Ib study in HCV patients, contribute to the attractive profile of ANA598 as an antiviral likely to be active in long-term studies in combination with pegylated interferon and ribavirin, and help position the program to be ready for Phase II in mid-2009.

Long-term Toxicology Studies

In September 2008, Anadys initiated long-term, chronic toxicology studies of ANA598, of 26 weeks duration in rats a
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
2. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
3. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
11. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... YORK , Oct. 30, 2014  The number ... States is growing steadily, thanks to drug ... as a result of the economic downturn, retail clinic ... a year of opportunities, as the number of retail ... researcher,s report, Retail Clinics Market Overview and 2014 ...
(Date:10/30/2014)... 30, 2014 Molecular Profiles Ltd., a subsidiary ... and Maryland -based Xceleron have announced ... during clinical development that will be launched at AAPS ... This partnership extends Molecular Profiles, new ROADMAP ... earlier this month. The company also has complementary collaborations ...
(Date:10/30/2014)... Oct. 30, 2014  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced an upcoming ... drug candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates ... be given by Sant P. Chawla , ... and principal investigator of the Company,s ongoing global, ...
Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
(Date:10/30/2014)... 2014 Global prebiotics market is expected ... a new study by Grand View Research, Inc. Positive ... sugar and fat free products owing to increased concerns ... prebiotics over the forecast period. , View full report ... & beverage was the largest application segment with market ...
(Date:10/30/2014)... October 30, 2014 The human brain ... more vigorously exercised to help maintain better mental health, ... book ‘Dementia Express: Lose Your Memory in 100 Ways’ ... reasoning and sometimes conflicting attitudes to help keep the ... mind, a reader must decipher the hidden logic within. ...
(Date:10/30/2014)... Sound Telecom, a leader in the call center industry, ... time they wonder, “Should I use an answering service?” The ... through a series of yes or no questions that ultimately ... are many considerations and scenarios that come into play when ... . This decision infographic serves as a bit of a ...
(Date:10/30/2014)... Amy Norton HealthDay Reporter ... common plastics, chemical during pregnancy may have effects on genital ... found that baby boys born to moms with greater exposure ... anogenital distance -- the space between the genitals and anus. ... a marker of exposure to androgens ("male" hormones) during pregnancy. ...
(Date:10/30/2014)... 2014 (HealthDay News) -- Eating a low-carb, high-fat diet ... according to new research. A review of ... diet, that focuses on foods like bacon, eggs, heavy ... seizures in adults whose condition doesn,t improve with medication. ... of people with epilepsy whose seizures are not stopped ...
Breaking Medicine News(10 mins):Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
... Healthcare ( www.siemens.com/healthcare ) ... the Workflow & Solutions Division, Siemens Healthcare, testified before the ... Representatives on the need for healthcare reform. ... ) , , During the hearing, "Comprehensive Health ...
... , Supporting individual quality of life and American business ... 24 The U.S. Women,s Chamber of Commerce submitted ... to restore American values and business competitiveness through the ... report include the support of Health Insurance Exchanges, guaranteed ...
... Inc. (NYSE: WPI ), a leading specialty ... Inc., has received approval today from the United States ... Application (ANDA) for levonorgestrel tablets, 0.75 mg, for women ... equivalent to Duramed Pharmaceuticals, PLAN B(R), which is indicated ...
... memories , WEDNESDAY, June 24 (HealthDay News) -- Researchers ... long-term storage of memories. , Their study showed that ... remember them less well than mice who can perform ... Circuit Genetics at MITs Picower Institute for Learning and ...
... shows better survival when compared to those who ... News) -- A new Canadian study adds compelling ... get clot-dissolving treatment for heart attacks should have ... "This study strengthens the guideline recommendations," said Dr. ...
... Mich., June 24 Validation and Compliance Institute (VCI), ... FDA regulated industries, will offer a series of Dietary ... (DBA), a division of NSF International. , ... the new GMP regulations for dietary supplements, which the ...
Cached Medicine News:Health News:Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 2Health News:Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 3Health News:U.S. Women's Chamber of Commerce Advocates Strong Healthcare Reforms in Support of American Values 2Health News:Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R) 2Health News:Sleep May Be Essential for Long-Term Memory 2Health News:Quick Angioplasty Best After Heart Attacks 2Health News:Quick Angioplasty Best After Heart Attacks 3Health News:Validation & Compliance Institute, LLC, to Provide Dietary Supplement GMP Training for NSF International 2
BD Vacutainer® Fluoride Tubes - Glass...
VACUETTE Trace Element tubes - Ridged (safety screw cap) are designed to test trace elements such as Cu, Zn, Pb, etc....
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: